期刊文献+

荧光原位杂交技术与细胞遗传学分析在骨髓增生异常综合征患者-5/5q-和-7/7q-检测中的评价应用 被引量:4

Detection of -5/5q- and -7/7q- in Myelodysplastic Syndromes by Fluorescence in Situ Hybridization and Cytogenetic Analysis
下载PDF
导出
摘要 目的 比较常规细胞遗传学分析(CCA)及荧光原位杂交(FISH)两种技术在骨髓增生异常综合征(MDS)染色体异常检测中的灵敏度和特异度.方法 40例MDS患者,CCA法采用骨髓短期培养法,核型分析采用R带技术.FISH法采用间期FISH,选取4组探针组合检测-5/5q-和-7/7q-.结果 采用CCA法,5号和7号染色体异常检出率为17.5%,而利用FISH技术,阳性率为35.0%.5号,7号染色体异常检出率分别由7.5%,10.0%升至15.0%,20.0%.两种方法之间的差异无统计学意义(P〉0.05).结论 CCA结合FISH能提高MDS染色体异常的检出率,与CCA相比,采用组合探针的FISH更为敏感和特异. Objective To compare the sensitivity and specificity of conventional cytogenetie analysis(CCA) and fluorescence in situ hybridization(FISH) technique in the detection of MDS. Methods Bone marrow cells from 40 patients were analyzed with CCA and FISH. Results Using CCA,karyotype abnormalities were found in 7 of 40 cases(17. 5%) ,and 14 of 40 cases (35%) were detected karyotype abnormalities by FIStt. There was no significant difference between CCA and FISH( P〉 0.05). Conclusion Combination of CCA and FISH could help the diagnosis and prognosis of MDS. FISH is more sensitive and specific for detection of chromosome abnormalities in MDS than CCA.
出处 《现代检验医学杂志》 CAS 2011年第6期86-88,共3页 Journal of Modern Laboratory Medicine
关键词 骨髓增生异常综合征 荧光原位杂交 细胞遗传学 染色体异常 MDS fluorescence in situ hybridization conventional cytogenetic analysis chromosome abnormality
  • 相关文献

参考文献7

二级参考文献21

  • 1邵宗鸿,付蓉.免疫相关性血细胞减少症——一种新认知的疾病(上)[J].中国医刊,2005,40(1):5-8. 被引量:56
  • 2曹梦苒,罗荣城,左强,张军一.荧光原位杂交与免疫组化检测乳腺癌组织Her-2/neu基因扩增或表达情况的比较[J].解放军医学杂志,2005,30(8):731-733. 被引量:6
  • 3曾瑄,赵大春,周炜洵,武莎斐,梁智勇,刘彤华.荧光原位杂交检测乳腺癌HER2基因状态[J].中华病理学杂志,2005,34(11):701-705. 被引量:65
  • 4Bennett JM,Catovsky D,Daniel MT,et al.Proposals for the classification of the myelodysplastic syndromes.Br J Haematol,1982,51(2):189-199.
  • 5Greenberg P,Cox C,LeBeau MM,et al.International scoring system for evaluating prognosis in myelodysplastic syndromes.Blood.1997,89(6):2079-2088.
  • 6Vardiman JW,Harris NL,Brunning RD.The World Health Organization (WHO) classification of the myeloid neoplasms.Blood,2002,100(7):2292-2302.
  • 7Malcovati L,Germing U,Kuendgen A,et al.Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.J Clin Oncol,2007,25(23):3503-3510.
  • 8Valent P,Horny HP,Bennett JM,et al.Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes:Consensus statements and report from a working conference.Leuk Res,2007,31(6):727-736.
  • 9Baur AS,Meugé-Moraw C,Schmidt PM,et al.CD34/QBEND10 immunostaining in bone marrowbiopsies:an additional parameter for the diagnosis and classification of myelodysplastie syndromes.Eur J Haematol,2000,64(2):71-79.
  • 10Verburgh E,Achten R,Maes B,et al.Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.J Clin Oncol,2003,21(2):273-282.

共引文献16

同被引文献37

  • 1Haase D. Cytogenetic features in myelodysplastic syndromes[-J].Ann Hematol, 2008,87 (7) 515-526.
  • 2Raza A,Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes[J. Nat Rev Cancer, 2012, 12 (12) : 849-859.
  • 3何涛.33例骨髓增生异常综合征的染色体核型分析[J].2012,33(1):2123.
  • 4徐卫,李建勇.骨髓增生异常综合征的细胞和分子遗传学[J].国际输血及血液学杂志,2008,31(3),195-198.
  • 5Kawankar N, Vundinti BR. Cytogenetic abnormalities in myelo- dysplastic syndrome: an overviewFJ. Hematology, 2011,16 (3) : 131-138.
  • 6Garcia-Manero G. Prognosis of myelodysplastic syndromes [J]. Hematology Am Soc Hematol Edue Program, 2010, 2010(1): 330-337.
  • 7Tefferi A, Vardiman JW. Myelodysplastic syndromes [J]. N Engl J Med, 2009, 361(19): 1872-1885.
  • 8Haase D. Cytogenetic features in myelodysplastic syndromes [J]. Ann Hematol, 2008, 87(7): 515-526.
  • 9Raza A, Galili N. The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes[J]. Nat Rev Cancer, 2012, 12(12): 849-859.
  • 10Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes [J]. Blood, 2009, 114(5): 937-951.

引证文献4

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部